# A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

> **NCT05562830** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 48 (estimated)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **BIOLOGICAL:** Zilovertamab vedotin
- **BIOLOGICAL:** Pembrolizumab
- **BIOLOGICAL:** MK-3120

## Key facts

- **NCT ID:** NCT05562830
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-16
- **Primary completion:** 2030-06-28
- **Final completion:** 2030-06-28
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05562830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05562830, "A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05562830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*